Core Viewpoint - Eisai Co., Ltd. and Biogen Inc. announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI has been designated for Priority Review by the National Medical Products Administration of China, which could significantly enhance patient access to treatment [1][2]. Group 1: Product Development and Approval - The subcutaneous formulation (SC-AI) of LEQEMBI allows for a once-weekly home administration, contrasting with the current intravenous method that requires hospital visits every two weeks [3]. - The injection time for each autoinjector is approximately 15 seconds, which could streamline the treatment process and reduce healthcare resource utilization [3]. - Eisai estimates that there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China in 2024, a number expected to rise with the aging population [4]. Group 2: Market Access and Insurance - LEQEMBI was launched in China in June 2024 and has been included in the "Commercial Insurance Innovative Drug List," effective January 2026, which supports access to innovative medicines [5]. - Commercial insurance companies are expected to develop insurance products covering LEQEMBI based on this new list [5]. Group 3: Collaboration and Regulatory Strategy - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [6][11]. - The U.S. FDA approved the Biologics License Application for subcutaneous maintenance dosing of LEQEMBI in August 2025, with a supplemental application for initiation treatment accepted in January 2026 [8]. Group 4: Scientific Background - Lecanemab is a humanized monoclonal antibody targeting aggregated forms of amyloid-beta, which is believed to play a significant role in cognitive decline associated with Alzheimer's disease [8][10]. - The reduction of protofibrils may prevent the progression of Alzheimer's disease by mitigating neuronal damage and cognitive dysfunction [10]. Group 5: Company Overview - Eisai's corporate concept focuses on patient-centric healthcare, aiming to address unmet medical needs, particularly in neurology and oncology [13]. - Biogen, founded in 1978, is a leading biotechnology company that emphasizes innovative science to transform patient lives and create shareholder value [16].

本文源自：金融界AI电报 复宏汉霖(02696.HK)公告，公司与日本制药公司EisaiCo.,Ltd.订立许可协议，公司将授予Eisai独家许 可，供其于区域及领域内商业化许可产品汉斯状®（斯鲁利单抗注射液）。Eisai将向本公司支付首付款 7500万美元，监管里程碑款项合计至多8001万美元，基于许可产品于区域内的各项监管里程碑达成情况 支付；商业销售里程碑款项合计至多2.3333亿美元，基于许可产品于区域内的年度净销售额水平达成情 况支付以及以许可产品于区域内的年度净销售额的两位数百分比计的特许权使用费。 ...

Eisai将向公司支付：(a) 首付款7500万美元，于许可协议订立后支付; (b) 监管里程碑款项合计至多8001 万美元，基于许可产品于区域内的各项监管里程碑达成情况支付; (c) 商业销售里程碑款项合计至多约 2.33亿美元，基于许可产品于区域内的年度净销售额水平达成情况支付;及 (d) 以许可产品于区域内的年 度净销售额的两位数百分比计的特许权使用费。 据悉，汉斯状® (斯鲁利单抗注射液)为公司自主开发的创新型抗PD-1单抗，其于中国境内(不包括中国 港澳台地区，下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小细胞肺癌(sq-NSCLC)、广泛期 小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC)及非鳞状非小细胞肺癌(nsq-NSCLC)。同时，汉斯状® 亦已分别于欧盟、英国、印度尼西亚、柬埔寨、泰国、马来西亚、新加坡、及印度等国家/地区获批上 市，并分别获美国、欧盟、瑞士及韩国等国家/地区的药品监督管理部门授予孤儿药资格认定。此外， 公司正有序推进汉斯状® 及相关联合疗法在全球开展的多项临床试验，广泛覆盖肺癌、食管癌、头颈 鳞癌、结直肠癌和胃癌等适应症。2025年12月，汉斯状®联合化疗于 ...

据悉，汉斯状® (斯鲁利单抗注射液)为公司自主开发的创新型抗PD-1单抗，其于中国境内(不包括中国 港澳台地区，下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小细胞肺癌(sq-NSCLC)、广泛期 小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC)及非鳞状非小细胞肺癌(nsq-NSCLC)。同时，汉斯状® 亦已分别于欧盟、英国、印度尼西亚、柬埔寨、泰国、马来西亚、新加坡、及印度等国家/地区获批上 市，并分别获美国、欧盟、瑞士及韩国等国家/地区的药品监督管理部门授予孤儿药资格认定。此外， 公司正有序推进汉斯状® 及相关联合疗法在全球开展的多项临床试验，广泛覆盖肺癌、食管癌、头颈 鳞癌、结直肠癌和胃癌等适应症。2025年12月，汉斯状®联合化疗于胃癌新辅助/辅助治疗的药品注册 申请获国家药品监督管理局(NMPA)受理，并已纳入优先审评审批程序。 本次与Eisai就许可产品于区域内的商业化合作将有助于进一步拓展公司产品的海外市场，增强公司产品 在国际市场的可及性和认可度，从而为公司收入的持续提升创造条件。 智通财经APP讯，复宏汉霖(02696)公布，公司于2026年2月5日与Eisai Co., Ltd ...

格隆汇2月5日丨复宏汉霖(02696.HK)宣布，公司于2026年2月5日与Eisai Co., Ltd.("Eisai")订立一份许可 协议，据此，公司同意向Eisai授出一项许可，供其于日本("区域")及领域(定义如下文)内开发、生产和 商业化汉斯状®(斯鲁利单抗注射液)("许可产品")。 本次与Eisai就许可产品于区域内的商业化合作将有助于进一步拓展公司产品的海外市场，增强公司产品 在国际市场的可及性和认可度，从而为公司收入的持续提升创造条件。 汉斯状®在中国境内的销售推广由公司自建商业化团队主导。截至公告日期，公司已分别与多个国际知 名合作伙伴就汉斯状®于全球超100个国家和地区的商业化达成合作。 根据许可协议，公司将授予Eisai：(a) 一项独家许可，供其于区域及领域内商业化许可产品；及(b) 仅就 上文(a)项所述目的，于区域及领域内开发和生产许可产品的共同排他许可(即公司亦有权开发和生产)。 Eisai将向公司支付：(a) 首付款7500万美元，于许可协议订立后支付；(b) 监管里程碑款项合计至多8001 万美元，基于许可产品于区域内的各项监管里程碑达成情况支付；(c) 商业销售里程碑款项合 ...

Core Viewpoint - The FDA has accepted for review Eisai's Supplemental Biologics License Application for LEQEMBI IQLIK, which, if approved, would be the first anti-amyloid treatment allowing at-home injections for Alzheimer's disease, with a decision expected by May 24, 2026 [2][3]. Group 1: Product Details - LEQEMBI IQLIK is a subcutaneous autoinjector for lecanemab, intended for weekly starting doses in treating early Alzheimer's disease [2][3]. - The proposed dosing regimen involves two 250 mg injections, allowing patients to choose between subcutaneous or intravenous administration throughout treatment [3][4]. - The injection time for each 250 mg dose is approximately 15 seconds, potentially reducing healthcare resource utilization compared to intravenous dosing [3]. Group 2: Clinical Data and Safety - Clinical data supporting the sBLA indicates that the 500 mg subcutaneous administration achieves equivalent exposure to the bi-weekly intravenous dosing, with similar clinical and biomarker benefits [4]. - The safety profile of subcutaneous administration is comparable to intravenous administration, with less than 2% incidence of systemic injection or infusion-related reactions [4]. - LEQEMBI is currently approved in 53 countries and regions, with ongoing regulatory reviews in 7 additional countries [6][30]. Group 3: Mechanism of Action - LEQEMBI targets both protofibrils and amyloid plaques, which are critical in the neurotoxic process of Alzheimer's disease, potentially impacting tau pathology [5][29]. - Protofibrils are identified as the most toxic species contributing to cognitive decline in Alzheimer's, and reducing them may mitigate neuronal damage [7]. Group 4: Collaboration and Development - Eisai leads the global development and regulatory submissions for lecanemab, with Biogen co-commercializing and promoting the product [6][33]. - The collaboration between Eisai and BioArctic has been ongoing since 2005, focusing on the development and commercialization of Alzheimer's treatments [34]. Group 5: Market Position - The approval of LEQEMBI IQLIK would enhance treatment options for Alzheimer's patients, particularly in the early stages of the disease, and could streamline the treatment process [2][3][4]. - The product's introduction aligns with the growing demand for innovative therapies in the Alzheimer's treatment landscape, addressing significant unmet medical needs [35][38].

Core Insights - Biogen Inc. is a leading biotechnology company focused on developing treatments for neurological diseases, particularly Alzheimer's disease, in collaboration with Eisai Co., Ltd. [1][6] - UBS has set a price target of $185 for Biogen, indicating optimism about the company's growth potential in the Alzheimer's treatment market [2] - The acceptance of the Biologics License Application for LEQEMBI's subcutaneous formulation in China is a significant milestone that could enhance Biogen's market presence in Asia [3][6] Financial Performance - Biogen's stock has shown resilience with a 15.1% increase in 2025, driven by the successful launch of LEQEMBI and a 29.9% increase in sales for Skyclarys, which reached $132.9 million in the third quarter [4][6] - Currently, Biogen's stock is trading at $182.61, reflecting a 4.57% increase, with fluctuations between $174.30 and $182.97 [5] - Over the past year, Biogen's stock reached a high of $185.17 and a low of $110.04, with a market capitalization of approximately $26.79 billion [5]

Core Viewpoint - Eisai and Biogen announced the acceptance of the Biologics License Application (BLA) for the subcutaneous formulation of LEQEMBI (lecanemab) by the National Medical Products Administration (NMPA) in China, which could allow for at-home administration of the treatment for Alzheimer's disease [1][2]. Group 1: Product Details - The subcutaneous autoinjector (SC-AI) formulation of LEQEMBI allows for a 500 mg dose (two 250 mg injections) to be administered weekly at home, providing an alternative to the current intravenous (IV) administration [2]. - Each autoinjector delivers a 250 mg injection in approximately 15 seconds, potentially reducing healthcare resources associated with IV dosing [2]. - LEQEMBI targets protofibrils of amyloid beta (Aβ), which are believed to contribute to cognitive decline in Alzheimer's disease [4]. Group 2: Market Potential - Eisai estimates that there were 17 million patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease in China in 2024, a number expected to rise with the aging population [3]. - The approval of the SC-AI formulation could expand treatment options for patients and caregivers, facilitating easier access to therapy [2]. Group 3: Collaboration and Development - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [3][8]. - The collaboration between Eisai and BioArctic, initiated in 2005, has been crucial for the development and commercialization of lecanemab [9]. Group 4: Regulatory Status - LEQEMBI has been approved in 52 countries and is under regulatory review in 8 countries, with recent approvals including subcutaneous maintenance dosing in the U.S. and inclusion in China's "Commercial Insurance Innovative Drug List" [6].

Core Points - The meeting aims to discuss Eisai's value creation initiatives and gather feedback for future planning [1] - Eisai emphasizes the social impact of its product LEQEMBI and its contributions to dementia initiatives, which enhance the company's competitiveness [2] Group 1 - The purpose of the Opinion Exchange meeting is to utilize feedback for improving management and future value creation reports [1] - Eisai's initiatives in the dementia area are highlighted as a key source of competitiveness, as detailed in the Value Creation Report 2025 [2] - The company focuses on non-financial capital, including R&D promotion, brand strengthening, and employee engagement, to enhance corporate value [2]

Core Insights - Eisai Co., Ltd. and Biogen Inc. announced that their anti-Aβ protofibril antibody LEQEMBI has been included in China's "Commercial Insurance Innovative Drug List," enhancing access to early Alzheimer's Disease treatment in the country [1][2] Group 1: Product and Market Impact - The inclusion of LEQEMBI in the Commercial Insurance Innovative Drug List is a significant step towards improving access to innovative medicines in China, addressing the coverage gap between basic reimbursement and innovative treatments [2] - Eisai estimates that there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer's Disease in China in 2024, a number expected to rise with the aging population [3] - LEQEMBI was launched in China in June 2024 and is currently available in the private market [3] Group 2: Development and Collaboration - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [4][9] - The drug is a result of a strategic research alliance between Eisai and BioArctic, targeting aggregated soluble and insoluble forms of amyloid-beta [7][10] - LEQEMBI has been approved in 51 countries and is under regulatory review in 9 additional countries, with various dosing regimens approved [7] Group 3: Clinical Studies and Research - Ongoing clinical studies include the Phase 3 AHEAD 3-45 study for individuals with preclinical Alzheimer's Disease, funded by the National Institute on Aging and conducted in partnership with the Alzheimer's Clinical Trial Consortium [8] - The Tau NexGen clinical study for Dominantly Inherited Alzheimer's Disease is also ongoing, incorporating lecanemab as a key therapy [8]